Complex generics and CDMO drive growth potential

Shilpa Medicare: Complex generics and CDMO drive growth potential Shilpa Medicare Limited (NSE: SHILPAMED) operates across pharmaceutical formulations, active pharmaceutical ingredients and biotechnology-related businesses. Its opportunities include complex generics, specialty products and contract development and manufacturing. **Why it matters:** Complex formulations and higher-value pharmaceutical products can support better business opportunities, but commercialisation timelines, regulatory approvals and research expenditure can affect returns. **My view:** The key is converting its product pipeline and manufacturing capabilities into consistent commercial revenue. Investors should track whether growth translates into improved operating margins and cash generation, rather than relying solely on pipeline potential. **What to watch:** Regulatory approvals, product launches, formulation revenue, CDMO business growth, operating margins and working-capital requirements. **Stance:** Specialty pharmaceuticals offer long-term potential, but execution, regulatory progress and valuation remain important factors in assessing Shilpa Medicare. Disclosure: I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security.